BNTX vs RPRX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BNTX · BioNTech$87.51 ▲ 1.92%
RPRX · Royalty Pharma$67.30 ▼ 0.40%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BNTX -16.7%
- RPRX +78.0%
Head to head
| Metric | BNTX | RPRX |
|---|---|---|
| Price | $87.51 | $67.30 |
| Change today | ▲ 1.92% | ▼ 0.40% |
| Market cap | $21.70B | $29.97B |
| Return, 3 months | -5.7% | +16.6% |
| Return, year to date | -8.1% | +76.6% |
| Return, 1 year | -15.2% | +77.9% |
| P/E (TTM) | -13.3 | 44.0 |
| P/B | 1.1 | 4.4 |
| P/E percentile vs own 5y | 41st | 84th |
| Dividend yield | – | 1.37% |
| Revenue growth (YoY, latest qtr) | -59.5% | +16.5% |
| Net profit growth (YoY) | -112.3% | -12.0% |
| Gross margin | 75.5% | – |
| Operating margin | -46.4% | 62.3% |
| Net margin | -63.6% | 32.0% |
| Return on equity | -9.3% | 12.3% |
| Analyst target vs. price | +43.8% | +5.0% |
| Analyst buy share | 73% | 100% |
| RSI (14) | 43 | 72 |
| 30-day volatility | 39.7% | 23.1% |
| Max drawdown, 1 year | -29.7% | -12.1% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- RPRX is the largest of the group by market value.
- RPRX has returned the most over the past year.
- BNTX carries the lowest trailing P/E.
- RPRX is growing revenue fastest.
- RPRX keeps the most profit per dollar of sales.
- RPRX has been the calmest stock over the last 30 days.